These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 30269270)

  • 1. Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent.
    Kristensen LE; Alten R; Puig L; Philipp S; Kvien TK; Mangues MA; van den Hoogen F; Pavelka K; Vulto AG
    BioDrugs; 2018 Oct; 32(5):397-404. PubMed ID: 30269270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars.
    Rezk MF; Pieper B
    Adv Ther; 2018 Jun; 35(6):749-753. PubMed ID: 29873005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nocebo effect: a clinical challenge in the era of biosimilars.
    Pouillon L; Socha M; Demore B; Thilly N; Abitbol V; Danese S; Peyrin-Biroulet L
    Expert Rev Clin Immunol; 2018 Sep; 14(9):739-749. PubMed ID: 30118338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The nocebo effect challenges the non-medical infliximab switch in practice.
    Boone NW; Liu L; Romberg-Camps MJ; Duijsens L; Houwen C; van der Kuy PHM; Janknegt R; Peeters R; Landewé RBM; Winkens B; van Bodegraven AA
    Eur J Clin Pharmacol; 2018 May; 74(5):655-661. PubMed ID: 29368188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review.
    Bakalos G; Zintzaras E
    Clin Ther; 2019 Jan; 41(1):155-173.e13. PubMed ID: 30551802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are we ready to close the discussion on the interchangeability of biosimilars?
    Ebbers HC; Schellekens H
    Drug Discov Today; 2019 Oct; 24(10):1963-1967. PubMed ID: 31254488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies.
    Odinet JS; Day CE; Cruz JL; Heindel GA
    J Manag Care Spec Pharm; 2018 Oct; 24(10):952-959. PubMed ID: 30247100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Nocebo Effect in a Non-Medical Switching Program from Originator to Biosimilar Infliximab in Inflammatory Bowel Disease.
    Dutt K; Srinivasan A; Van Langenberg D
    BioDrugs; 2022 Sep; 36(5):639-644. PubMed ID: 35960446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients.
    Pouillon L; Danese S; Hart A; Fiorino G; Argollo M; Selmi C; Carlo-Stella C; Loeuille D; Costanzo A; Lopez A; Vegni E; Radice S; Gilardi D; Socha M; Fazio M; González-Lorenzo M; Bonovas S; Magro F; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2019 May; 49(9):1181-1187. PubMed ID: 30932219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group.
    D'Amico F; Pouillon L; Argollo M; Hart A; Fiorino G; Vegni E; Radice S; Gilardi D; Fazio M; Leone S; Bonovas S; Magro F; Danese S; Peyrin-Biroulet L
    Dig Liver Dis; 2020 Feb; 52(2):138-142. PubMed ID: 31812570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Clinical Implications of Nocebo Effects for Biosimilar Therapy.
    Colloca L; Panaccione R; Murphy TK
    Front Pharmacol; 2019; 10():1372. PubMed ID: 31849647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biosimilars and the nocebo effect].
    Braun J; Tsiami S; Buehring B; Kiefer D; Andreica I; Baraliakos X; Kiltz U
    Z Rheumatol; 2020 Apr; 79(3):267-275. PubMed ID: 31802197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice.
    Solitano V; D'Amico F; Fiorino G; Peyrin-Biroulet L; Danese S
    Expert Rev Clin Immunol; 2020 Oct; 16(10):1019-1028. PubMed ID: 32954893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next?
    D'Amico F; Solitano V; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2021 Jan; 21(1):47-55. PubMed ID: 32857634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical Practice.
    Barbier L; Simoens S; Vulto AG; Huys I
    BioDrugs; 2020 Dec; 34(6):797-808. PubMed ID: 33063267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.
    Scrivo R; Castellani C; Mancuso S; Sciarra G; Giardina F; Bevignani G; Ceccarelli F; Spinelli FR; Alessandri C; Di Franco M; Riccieri V; Priori R; Conti F
    Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nocebos in rheumatology: emerging concepts and their implications for clinical practice.
    Kravvariti E; Kitas GD; Mitsikostas DD; Sfikakis PP
    Nat Rev Rheumatol; 2018 Dec; 14(12):727-740. PubMed ID: 30361674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
    Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
    Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars: From Production to Patient.
    Sheridan M; Massich M; Ashourian N
    J Infus Nurs; 2024 Jan-Feb 01; 47(1):19-29. PubMed ID: 38211611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar.
    Petit J; Antignac M; Poilverd RM; Baratto R; Darthout S; Desouches S; Louati K; Deparis N; Berenbaum F; Beauvais C
    RMD Open; 2021 Jan; 7(1):. PubMed ID: 33495387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.